Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | PIR | O00625 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | STK16 | O75716 | 1/20 | 0.39 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3705466 | 0.88 | CYP3A4 (0.52) | CYP3A4BRAFCYP2C19CYP2C9AXL | |
| SCHEMBL2351343 | 0.88 | CYP2C9 (0.48) | CYP3A4BRAFCYP2C19CYP2C9AXL | |
| SCHEMBL299382 | 0.86 | BRAF (0.51) | CYP3A4BRAFCYP2C19CYP2C9AXL | |
| SCHEMBL2357075 | 0.86 | BRAF (0.49) | CYP3A4BRAFCYP2C19CYP2C9PAK1 | |
| SCHEMBL2883747 | 0.86 | CYP2C9 (0.46) | CYP3A4BRAFCYP2C19CYP2C9AXL | |
| SCHEMBL3507602 | 0.85 | CYP2C9 (0.45) | CYP3A4CYP2C9AXLPAK1AAK1 | |
| SCHEMBL3506675 | 0.84 | AXL (0.58) | CYP2C9AXLPAK1AAK1PLK4 | |
| SCHEMBL299151 | 0.83 | CYP2C9 (0.66) | CYP3A4BRAFCYP2C19CYP2C9PAK1 | |
| SCHEMBL4570620 | 0.83 | CYP2C9 (0.44) | CYP3A4BRAFCYP2C19CYP2C9AXL | |
| SCHEMBL293715 | 0.83 | BRAF (0.64) | CYP3A4BRAFCYP2C19CYP2C9PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP3A4 3611/4885BRAF 1/4885CYP2C19 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.